With CyberKnife, it is possible to treat cancer that is difficult to reach—without surgery. It is one of the newest and most advanced technologies in the field of radiation therapy.
CyberKnife works with great precision and can be an alternative for common treatment options of the prostate, such as prostatectomy. Even advanced prostate carcinomas that have already metastasized—i.e. have already spread throughout the body—can potentially be treated. The advantage is that the side effects are reduced, compared to common radiation therapies, because the treatment uses highly focussed radiation beams, which make it possible to spare the surrounding organs. Another advantage over other radiation therapies or surgery is that the treatment is on an outpatient basis and under local anesthesia.
Compared to focal treatments like IRE, CyberKnife therapy may require more than one session. While adverse events are less severe compared to other radiation therapies, some adverse events can still apply—mainly due to delayed radiation effects—that do not occur with NanoKnife.
Progression-free survival at 5 years
Numbers compare biochemical progression-free survival at 5 years of PCa patients with low risk, organ-confined disease.
Citation for CyberKnife numbers: Freeman, Debra E., and Christopher R. King. "Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes." Radiation Oncology 6.1 (2011): 3.